These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 9404936)

  • 1. Allogeneic bone marrow transplantation for AL amyloidosis.
    Guillaume B; Straetmans N; Jadoul M; Cosyns JP; Ferrant A
    Bone Marrow Transplant; 1997 Nov; 20(10):907-8. PubMed ID: 9404936
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High-dose therapy and autologous transplantation in amyloidosis-AL.
    Majolino I; Marcenò R; Pecoraro G; Scimé R; Vasta S; Liberti G; Rizzo A; Indovina A; Caronia F
    Haematologica; 1993; 78(1):68-71. PubMed ID: 8098314
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reduced intensity allogeneic stem cell transplantation for systemic primary amyloidosis refractory to high-dose melphalan.
    Kawai Y; Kinoshita K; Arai H; Kuwata A; Fukuoka Y; Yamaoka M; Imamura S; Tsutani H; Ueda T
    Eur J Haematol; 2004 Jun; 72(6):448-50. PubMed ID: 15128426
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Renal response after high-dose melphalan and stem cell transplantation is a favorable marker in patients with primary systemic amyloidosis.
    Leung N; Dispenzieri A; Fervenza FC; Lacy MQ; Villicana R; Cavalcante JL; Gertz MA
    Am J Kidney Dis; 2005 Aug; 46(2):270-7. PubMed ID: 16112045
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High-dose melphalan with autologous stem cell transplantation after VAD induction chemotherapy for treatment of amyloid light chain amyloidosis: a single centre prospective phase II study.
    Perz JB; Schonland SO; Hundemer M; Kristen AV; Dengler TJ; Zeier M; Linke RP; Ho AD; Goldschmidt H
    Br J Haematol; 2004 Dec; 127(5):543-51. PubMed ID: 15566357
    [TBL] [Abstract][Full Text] [Related]  

  • 6. AL amyloidosis associated with B-cell lymphoproliferative disorders: frequency and treatment outcomes.
    Sanchorawala V; Blanchard E; Seldin DC; O'Hara C; Skinner M; Wright DG
    Am J Hematol; 2006 Sep; 81(9):692-5. PubMed ID: 16795060
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An overview of the use of high-dose melphalan with autologous stem cell transplantation for the treatment of AL amyloidosis.
    Sanchorawala V; Wright DG; Seldin DC; Dember LM; Finn K; Falk RH; Berk J; Quillen K; Skinner M
    Bone Marrow Transplant; 2001 Oct; 28(7):637-42. PubMed ID: 11704785
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rapid reversal of nephrotic syndrome due to primary systemic AL amyloidosis after VAD and subsequent high-dose chemotherapy with autologous stem cell support.
    Sezer O; Schmid P; Shweigert M; Heider U; Eucker J; Harder H; Sinha P; Radtke H; Possinger K
    Bone Marrow Transplant; 1999 May; 23(9):967-9. PubMed ID: 10338056
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Severity of baseline proteinuria predicts renal response in immunoglobulin light chain-associated amyloidosis after autologous stem cell transplantation.
    Leung N; Dispenzieri A; Lacy MQ; Kumar SK; Hayman SR; Fervenza FC; Cha SS; Gertz MA
    Clin J Am Soc Nephrol; 2007 May; 2(3):440-4. PubMed ID: 17699449
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum free light-chain responses after high-dose intravenous melphalan and autologous stem cell transplantation for AL (primary) amyloidosis.
    Sanchorawala V; Seldin DC; Magnani B; Skinner M; Wright DG
    Bone Marrow Transplant; 2005 Oct; 36(7):597-600. PubMed ID: 16044137
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Successful heart transplantation following melphalan plus dexamethasone therapy in systemic AL amyloidosis.
    Mignot A; Bridoux F; Thierry A; Varnous S; Pujo M; Delcourt A; Gombert JM; Goujon JM; Favreau F; Touchard G; Herpin D; Jaccard A
    Haematologica; 2008 Mar; 93(3):e32-5. PubMed ID: 18310532
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term outcome of autologous stem cell transplantation in light chain deposition disease.
    Lorenz EC; Gertz MA; Fervenza FC; Dispenzieri A; Lacy MQ; Hayman SR; Gastineau DA; Leung N
    Nephrol Dial Transplant; 2008 Jun; 23(6):2052-7. PubMed ID: 18178602
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Successful reduced intensity allogeneic stem cell transplantation for systemic AL amyloidosis.
    Imamura T; Ogata M; Kohno K; Tomo T; Ohtsuka E; Kikuchi H; Kadota J
    Am J Hematol; 2006 Apr; 81(4):281-3. PubMed ID: 16550508
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Syngeneic hematopoietic stem-cell transplantation for non-Hodgkin's lymphoma: a comparison with allogeneic and autologous transplantation--The Lymphoma Working Committee of the International Bone Marrow Transplant Registry and the European Group for Blood and Marrow Transplantation.
    Bierman PJ; Sweetenham JW; Loberiza FR; Taghipour G; Lazarus HM; Rizzo JD; Schmitz N; van Besien K; Vose JM; Horowitz M; Goldstone A;
    J Clin Oncol; 2003 Oct; 21(20):3744-53. PubMed ID: 12963703
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early intensification and autologous stem cell transplantation in patients with systemic AL amyloidosis: a single-centre experience.
    Frossard V; Ketterer N; Rosselet A; Meier P; Cairoli A; Duchosal MA; Kovacsovics T
    Ann Hematol; 2009 Jul; 88(7):681-5. PubMed ID: 19066891
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Autologous stem-cell transplantation in progressing amyloidosis is associated with severe transplant-related toxicity.
    Worel N; Schulenburg A; Mitterbauer M; Keil F; Rabitsch W; Kalhs P; Gisslinger H; Raderer M; Geissler K; Höcker P; Zielinski CC; Oberbauer R; Greinix HT
    Wien Klin Wochenschr; 2006 Feb; 118(1-2):49-53. PubMed ID: 16489526
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Toxic megacolon: a life-threatening complication of high-dose therapy and autologous stem cell transplantation among patients with AL amyloidosis.
    Hayes-Lattin BM; Curtin PT; Fleming WH; Leis JF; Stepan DE; Schubach S; Maziarz RT
    Bone Marrow Transplant; 2002 Sep; 30(5):279-85. PubMed ID: 12209349
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High-dose therapy in multiple myeloma and primary amyloidosis: an overview.
    Kyle RA
    Semin Oncol; 1999 Feb; 26(1):74-83. PubMed ID: 10073564
    [TBL] [Abstract][Full Text] [Related]  

  • 19. AL amyloidosis manifesting as systemic lymphadenopathy.
    Matsuda M; Gono T; Shimojima Y; Yoshida T; Katoh N; Hoshii Y; Yamada T; Ikeda S
    Amyloid; 2008 Jun; 15(2):117-24. PubMed ID: 18484338
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Autologous transplantation for primary systemic AL amyloidosis is feasible outside a major amyloidosis referral centre: the Calgary BMT Program experience.
    Chow LQ; Bahlis N; Russell J; Chaudhry A; Morris D; Brown C; Stewart DA
    Bone Marrow Transplant; 2005 Oct; 36(7):591-6. PubMed ID: 16062177
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.